期刊
NEURODEGENERATIVE DISEASES
卷 7, 期 1-3, 页码 136-138出版社
KARGER
DOI: 10.1159/000289223
关键词
Alzheimer's disease; Amyloid imaging; Positron emission tomography; Pittsburgh compound B; Mild cognitive impairment; Early diagnostic markers; CSF biomarkers
资金
- Swedish Research Council [05817]
- Stone's Foundation
- Alzheimer Foundation in Sweden
- Brain Foundation
- Foundation for Old Servants
- Foundation for Swedish Brain Power
- Knut and Alice Wallenberg Foundation
- EC [LSHB-CT-2005-512146, QLK6-CT-2000-00502]
Amyloid imaging has provided evidence for early detection of amyloid (A beta) load in prodromal Alzheimer's disease (AD). Several amyloid tracers have been developed for studies with positron emission tomography (PET). Early detection of at-risk subjects will be important in the future for a successful treatment of AD. The high A beta load in the brain measured by PET in patients with mild cognitive impairment that later will convert to AD suggests early, significant, ongoing pathological processes prior to cognitive impairment. PET A beta imaging will also be used for discrimination of AD from other dementia disorders, as well for the evaluation of anti-A beta drugs. Copyright (C) 2010 S. Karger AG, Basel
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据